Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types

Key Points

• Moderna’s intismeran cancer vaccine produced statistically significant and clinically meaningful Phase III results in adjuvant melanoma versus KEYTRUDA, supporting its T-cell-priming approach.
• The company and Merck are testing intismeran across nine trials and multiple tumor types, with upcoming Phase II readouts in renal cell carcinoma and bladder cancer potentially showing whether the benefits extend beyond melanoma.
• Moderna has treated about 3,000 patients and built an automated manufacturing facility to support potential commercialization, while its expanding respiratory vaccine portfolio remains central to its goal of reaching break-even in 2028.

Moderna NASDAQ: MRNA President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort to use T-cell priming in multiple tumor types.

Speaking at a Morgan Stanley event, Hoge said the melanoma study was the first to show a statistically significant and clinically meaningful benefit over Merck’s KEYTRUDA in the adjuvant melanoma setting, according to Moderna and its partner Merck. He described the results as validation of Moderna’s decade-long scientific hypothesis that priming T cells to recognize tumor-specific mutations can generate a substantial anti-cancer response.

“It’s not a checkpoint inhibitor,” Hoge said of the approach. “This is T-cell priming, not T-cell exhaustion.”

Broad Cancer Development Program

Moderna and Merck have nine ongoing clinical trials involving intismeran, including multiple late-stage studies. The program includes three randomized Phase III trials in lung cancer as well as studies in melanoma, renal cell carcinoma and bladder cancer.

Hoge said the company remains focused on reaching break-even in 2028, a target he said is based on the expected strength of Moderna’s infectious-disease vaccine business. Investments already made in intismeran and its clinical program are included in that outlook, he said.

While Moderna may consider expanding investment in the cancer vaccine program, Hoge said decisions would remain data-dependent. Potential future areas include monotherapy use and treatment in earlier-stage disease, including Stage 1 cancer.

The company expects the full melanoma data to be presented at a future medical meeting, though Hoge did not identify a specific venue. He said investors and clinicians will likely evaluate whether Phase III results resemble the earlier Phase II findings, how outcomes vary by disease stage and patient subgroups, and the timing and shape of separation in recurrence-related curves over time.

Hoge said the Phase II melanoma analyses showed favorable hazard ratios across tumor mutational burden, PD-1 status and tumor inflammation measures. However, he cautioned that it remains unclear how broadly the findings will apply across tumor types, particularly those considered less immunologically active.

Upcoming Bladder and Kidney Cancer Readouts

Among nearer-term data points, Hoge highlighted fully enrolled, event-driven Phase II studies in renal cell carcinoma and muscle-invasive bladder cancer. Each trial has roughly 300 patients randomized one-to-one against standard care, with KEYTRUDA serving as the comparator in the renal cell and muscle-invasive bladder studies.

He said these studies could help determine whether intismeran can add to the benefit of PD-1 therapy beyond melanoma. Renal cell carcinoma has lower tumor mutational burden than melanoma, although Hoge noted that mutations such as frameshifts and insertions or deletions can also create antigens that the immune system may recognize.

Moderna is also conducting a Phase II trial in non-muscle-invasive bladder cancer evaluating intismeran as monotherapy. Hoge said that study could provide insight into whether the therapy can be used earlier in disease and without a checkpoint inhibitor.

On potential regulatory paths, Hoge said a melanoma approval could address many of the manufacturing, safety and chemistry-related elements needed for future applications. Whether individual Phase II studies could support registration would depend on the strength and statistical significance of their clinical evidence, he said.

Manufacturing and Retreatment Potential

Hoge said Moderna has treated about 3,000 patients with intismeran, including an estimated 1,500 to 2,000 over the past 18 months, through its global clinical-trial system across more than 40 countries. The company has built a purpose-designed, automated manufacturing facility in Marlborough that is currently supplying trials.

He said the first of seven manufacturing suites at the facility should have sufficient capacity for an initial commercial launch, while additional capacity could be added with about 12 months of lead time. Hoge contrasted intismeran’s manufacturing process with CAR-T cell therapies, saying the final product uses similar chemical material across patients while the genetic sequence is individualized.

Moderna expects the long-term margin profile for intismeran to be competitive with other complex biologics rather than cell therapies, though Hoge said pricing discussions would be premature before more clinical data are available.

Hoge also said a patient whose cancer recurs could potentially receive a newly designed personalized vaccine targeting mutations in the relapsed tumor, though he emphasized that Moderna does not yet have clinical data supporting such retreatment.

Respiratory Vaccine Portfolio Expands

Beyond oncology, Hoge said Moderna now has five product approvals across COVID-19, influenza, respiratory syncytial virus, a flu/COVID combination product and its next-generation COVID vaccine, mNEXSPIKE. He said the expanded portfolio improves the company’s ability to pursue portfolio-based contracting with governments, health systems and pharmacies.

Moderna’s current guidance calls for up to 10% top-line growth this year, Hoge said. He pointed to the U.S. approval of mFluSiva, Moderna’s influenza vaccine for older adults, and the European launch of its flu/COVID combination vaccine as potential contributors to the company’s commercial outlook.

Hoge said mFluSiva’s mRNA-based production process avoids egg-based manufacturing, which he said can contribute to antigenic mismatch. For the combination vaccine, he cited the potential benefit of delivering flu and COVID protection in one shot while reducing storage and administration needs for health systems.

About Moderna (NASDAQ:MRNA)

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.